HRP20160932T1 - Kombinirana terapija za liječenje raka dojke - Google Patents
Kombinirana terapija za liječenje raka dojke Download PDFInfo
- Publication number
- HRP20160932T1 HRP20160932T1 HRP20160932TT HRP20160932T HRP20160932T1 HR P20160932 T1 HRP20160932 T1 HR P20160932T1 HR P20160932T T HRP20160932T T HR P20160932TT HR P20160932 T HRP20160932 T HR P20160932T HR P20160932 T1 HRP20160932 T1 HR P20160932T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- tgfß
- breast cancer
- antagonist
- agent
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title claims 5
- 208000026310 Breast neoplasm Diseases 0.000 title claims 5
- 238000002648 combination therapy Methods 0.000 title 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 12
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 12
- 239000005557 antagonist Substances 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 4
- 229960004117 capecitabine Drugs 0.000 claims 4
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims 4
- 229960002014 ixabepilone Drugs 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Claims (16)
1. Farmaceutski pripravak za liječenje raka dojke kod subjekta, koji sadrži: terapijski učinkovitu količinu antagonista transformirajućeg faktora rasta beta (TGFß), kapecitabina, te iksabepilon, naznačen time da je navedeni antagonist TGFß prisutan u količini koja učinkovito pojačava učinkovitost kapecitabina i iksabepilona u liječenju navedenog raka dojke.
2. Pripravak prema zahtjevu 1, naznačen time da navedeni antagonist TGFß je sredstvo koje blokira vezivanje TGFß proteina na njegov receptor.
3. Pripravak prema zahtjevu 2, naznačen time da navedeno sredstvo je protein.
4. Pripravak prema zahtjevu 3, naznačen time da navedeno sredstvo je anti-TGFß protutijelo.
5. Pripravak prema zahtjevu 4, naznačen time da navedeno protutijelo je pan neutralizirajuće anti-TGFß protutijelo.
6. Pripravak prema zahtjevu 4, naznačen time da navedeno protutijelo je anti-TGFß monoklonsko protutijelo.
7. Pripravak prema zahtjevu 6, naznačen time da navedeno protutijelo je humanizirano protutijelo koje sadrži jedan ili više CDR-ova iz 1D11.
8. Pripravak prema zahtjevu 2, naznačen time da navedeni TGFß protein je TGFß-1, -2, -3, ili njihova kombinacija.
9. Komplet za liječenje raka dojke kod subjekta, koji sadrži: terapijski učinkovitu količinu antagonista transformirajućeg faktora rasta beta (TGFß), kapecitabin, te iksabepilon, naznačen time da je navedeni antagonist TGFß prisutan u količini koja učinkovito pojačava učinkovitost kapecitabina i iksabepilona u liječenju navedenog raka dojke.
10. Komplet prema zahtjevu 9, naznačen time da navedeni TGFß antagonist je sredstvo koje blokira vezanje TGFß proteina na njegov receptor.
11. Komplet prema zahtjevu 10, naznačen time da navedeno sredstvo je protein.
12. Komplet prema zahtjevu 11, naznačen time da navedeno sredstvo je anti-TGFß protutijelo.
13. Komplet prema zahtjevu 12, naznačen time da navedeno protutijelo je pan neutralizirajuće anti-TGFß protutijelo.
14. Komplet prema zahtjevu 13, naznačen time da navedeno protutijelo je anti-TGFß monoklonsko protutijelo.
15. Komplet prema zahtjevu 14, naznačen time da navedeno protutijelo je humanizirano protutijelo koje sadrži jedan ili više CDR-ova iz 1D11.
16. Komplet prema zahtjevu 10, naznačen time da navedeni TGFß protein je TGFß-1, -2, -3, ili njihova kombinacija.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31351510P | 2010-03-12 | 2010-03-12 | |
EP14187507.0A EP2835053B1 (en) | 2010-03-12 | 2011-03-08 | Combination therapy for treating breast cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20160932T1 true HRP20160932T1 (hr) | 2016-10-07 |
Family
ID=44563812
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160932TT HRP20160932T1 (hr) | 2010-03-12 | 2016-07-22 | Kombinirana terapija za liječenje raka dojke |
HRP20181757TT HRP20181757T1 (hr) | 2010-03-12 | 2018-10-24 | Kombinirana terapija za liječenje raka dojke |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20181757TT HRP20181757T1 (hr) | 2010-03-12 | 2018-10-24 | Kombinirana terapija za liječenje raka dojke |
Country Status (18)
Country | Link |
---|---|
US (3) | US8911736B2 (hr) |
EP (4) | EP3117709B1 (hr) |
JP (2) | JP5917418B2 (hr) |
CY (1) | CY1117831T1 (hr) |
DK (2) | DK2835053T3 (hr) |
ES (2) | ES2584433T3 (hr) |
HK (1) | HK1206936A1 (hr) |
HR (2) | HRP20160932T1 (hr) |
HU (2) | HUE027831T2 (hr) |
LT (1) | LT3117709T (hr) |
ME (1) | ME02464B (hr) |
PL (2) | PL3117709T3 (hr) |
PT (2) | PT2835053T (hr) |
RS (2) | RS54972B1 (hr) |
SI (2) | SI3117709T1 (hr) |
SM (1) | SMT201600253B (hr) |
TR (1) | TR201816180T4 (hr) |
WO (1) | WO2011112609A1 (hr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE027831T2 (en) * | 2010-03-12 | 2016-11-28 | Genzyme Corp | Combination therapy for breast cancer |
WO2013078286A1 (en) * | 2011-11-22 | 2013-05-30 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling |
TWI664979B (zh) | 2013-03-11 | 2019-07-11 | 健臻公司 | 經生物工程之抗-TGF-β抗體及抗原結合片段 |
WO2016094697A2 (en) | 2014-12-10 | 2016-06-16 | The Regents Of The University Of Colorado, A Body Corporate | Targeting breast cancer therapy based on stromal subtypes and cd146 composition |
GB201503438D0 (en) * | 2015-02-27 | 2015-04-15 | Ucl Business Plc | Antibodies |
US10616698B2 (en) * | 2015-03-18 | 2020-04-07 | Med-El Elektromedizinische Geraete Gmbh | Fixation of a bone conduction floating mass transducer |
KR102647231B1 (ko) | 2018-08-02 | 2024-03-13 | 삼성전자주식회사 | 반도체 소자 및 이의 제조방법 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US247550A (en) * | 1881-09-27 | Bakee beos | ||
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
CA1327358C (en) | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
WO1990000194A1 (en) | 1988-06-28 | 1990-01-11 | La Jolla Cancer Research Foundation | Suppression of cell proliferation by decorin |
US5583103A (en) | 1988-06-28 | 1996-12-10 | La Jolla Cancer Research Foundation | Inhibition of transforming growth factor beta activity |
US5654270A (en) | 1988-06-28 | 1997-08-05 | La Jolla Cancer Research Foundation | Use of fibromodulin to prevent or reduce dermal scarring |
US5705609A (en) | 1988-06-28 | 1998-01-06 | La Jolla Cancer Research Foundation | Decorin fragments inhibiting cell regulatory factors |
US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
EP0502036B1 (en) | 1989-11-22 | 1995-12-20 | Genentech, Inc. | Latency associated peptide and uses therefor |
EP0610427B1 (en) | 1991-10-31 | 2003-04-02 | Whitehead Institute For Biomedical Research | Tgf-beta type iii receptor, cdna encoding it and uses therefor |
US6008011A (en) | 1991-10-31 | 1999-12-28 | Whitehead Institute For Biomedical Research | TGF-β type II receptor cDNAs |
DE69228700T2 (de) | 1991-12-04 | 1999-09-09 | Jolla Cancer Res Found | Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände |
GB9205800D0 (en) | 1992-03-17 | 1992-04-29 | British Tech Group | Treatment of fibrotic disorders |
WO1993019177A1 (en) | 1992-03-18 | 1993-09-30 | The General Hospital Corporation | FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY |
AU3943793A (en) | 1992-04-01 | 1993-11-08 | Whittier Institute For Diabetes And Endocrinology, The | Methods of inhibiting or enhancing scar formation in the CNS |
US5869462A (en) | 1992-09-10 | 1999-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
US5821234A (en) | 1992-09-10 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
AU5587094A (en) | 1992-10-26 | 1994-05-24 | Kirin Brewery Company, Limited | Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide |
JPH08504763A (ja) * | 1992-10-29 | 1996-05-21 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | 治療薬としてのTGF−βレセプターフラグメントの使用 |
US5830847A (en) | 1992-10-30 | 1998-11-03 | Hsc Research & Development Limited Partnership | Soluble TGF-β-binding endoglin polypeptides and homodimers |
AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
AU6794594A (en) | 1993-04-30 | 1994-11-21 | Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh | Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (tgf-beta ) |
EP0737071A1 (en) | 1993-06-15 | 1996-10-16 | Il- Yang Pharm. Co., Ltd. | Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
CA2189340A1 (en) | 1994-05-04 | 1995-11-16 | James W. Dennis | Modulators of cytokines of the tgf-.beta. superfamily and methods for assaying for same |
US5772995A (en) | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
CA2156767A1 (en) | 1994-08-25 | 1996-02-26 | Kenichi Matsunaga | Binding agent for growth factor |
JPH08119984A (ja) | 1994-08-31 | 1996-05-14 | Nkk Corp | ストレプトミセス属放線菌及びこの菌由来のTGF−β 阻害剤 |
US5968770A (en) | 1995-02-10 | 1999-10-19 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target |
US5824655A (en) | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
US5824299A (en) | 1995-06-22 | 1998-10-20 | President & Fellows Of Harvard College | Modulation of endothelial cell proliferation with IP-10 |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
JP2000510112A (ja) | 1996-04-30 | 2000-08-08 | ジェンザイム コーポレーション | TGF―β拮抗物質としてのプロラクチンの使用方法 |
JPH1067674A (ja) | 1996-06-19 | 1998-03-10 | Advanced Sukin Res Kenkyusho:Kk | 細胞外マトリツクスの異常蓄積抑制剤 |
US5807708A (en) | 1996-07-30 | 1998-09-15 | Millennium Pharmaceuticals, Inc. | Conservin nucleic acid molecules and compositions |
AU3215597A (en) | 1996-08-30 | 1998-03-19 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
ES2253788T3 (es) | 1996-10-25 | 2006-06-01 | Ethicon, Inc. | Ensayo de agente anti-fibrotico. |
US5948639A (en) | 1997-04-10 | 1999-09-07 | Millennium Pharmaceuticals, Inc. | TGF-β pathway genes |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
EP1278518B1 (en) * | 2000-02-28 | 2006-11-08 | Pfizer Enterprises SARL | Synergistic combination for the treatment of colorectal cancer |
WO2005050200A2 (en) * | 2003-11-13 | 2005-06-02 | Genentech, Inc. | Screening assays and methods of tumor treatment |
US20070196269A1 (en) * | 2003-12-19 | 2007-08-23 | Karl-Hermann Schlingensiepen | Pharmaceutical composition |
RU2386638C2 (ru) * | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
CA2588400A1 (en) * | 2004-11-18 | 2006-05-26 | Bristol-Myers Squibb Company | Enteric coated bead comprising ixabepilone, and preparation thereof |
ES2711213T3 (es) | 2005-02-08 | 2019-04-30 | Genzyme Corp | Anticuerpos de TGFbeta |
EP2023923A2 (en) * | 2006-05-25 | 2009-02-18 | Bristol-Myers Squibb Company | Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals |
WO2008145403A1 (en) | 2007-06-01 | 2008-12-04 | Synthon B.V. | Processes related to making capecitabine |
DE102008002395A1 (de) * | 2008-06-12 | 2009-12-17 | Biotronik Vi Patent Ag | Wirkstoffbeladenes Implantat |
HUE027831T2 (en) * | 2010-03-12 | 2016-11-28 | Genzyme Corp | Combination therapy for breast cancer |
-
2011
- 2011-03-08 HU HUE14187507A patent/HUE027831T2/en unknown
- 2011-03-08 RS RS20160591A patent/RS54972B1/sr unknown
- 2011-03-08 WO PCT/US2011/027589 patent/WO2011112609A1/en active Application Filing
- 2011-03-08 EP EP16166917.1A patent/EP3117709B1/en active Active
- 2011-03-08 PL PL16166917T patent/PL3117709T3/pl unknown
- 2011-03-08 TR TR2018/16180T patent/TR201816180T4/tr unknown
- 2011-03-08 EP EP18182899.7A patent/EP3406141B1/en active Active
- 2011-03-08 LT LTEP16166917.1T patent/LT3117709T/lt unknown
- 2011-03-08 SI SI201131601T patent/SI3117709T1/sl unknown
- 2011-03-08 DK DK14187507.0T patent/DK2835053T3/en active
- 2011-03-08 PT PT141875070T patent/PT2835053T/pt unknown
- 2011-03-08 ME MEP-2016-150A patent/ME02464B/me unknown
- 2011-03-08 SI SI201130900A patent/SI2835053T1/sl unknown
- 2011-03-08 EP EP11753944.5A patent/EP2544541B1/en active Active
- 2011-03-08 ES ES14187507.0T patent/ES2584433T3/es active Active
- 2011-03-08 EP EP14187507.0A patent/EP2835053B1/en active Active
- 2011-03-08 DK DK16166917.1T patent/DK3117709T3/en active
- 2011-03-08 ES ES16166917.1T patent/ES2694288T3/es active Active
- 2011-03-08 HU HUE16166917A patent/HUE040107T2/hu unknown
- 2011-03-08 PT PT16166917T patent/PT3117709T/pt unknown
- 2011-03-08 US US13/634,392 patent/US8911736B2/en active Active
- 2011-03-08 JP JP2012557175A patent/JP5917418B2/ja active Active
- 2011-03-08 RS RS20181301A patent/RS57942B1/sr unknown
- 2011-03-08 PL PL14187507.0T patent/PL2835053T3/pl unknown
-
2014
- 2014-12-05 US US14/562,306 patent/US9539325B2/en active Active
-
2015
- 2015-08-05 HK HK15107519.0A patent/HK1206936A1/zh unknown
-
2016
- 2016-04-06 JP JP2016076356A patent/JP6289528B2/ja active Active
- 2016-07-22 HR HRP20160932TT patent/HRP20160932T1/hr unknown
- 2016-07-26 CY CY20161100731T patent/CY1117831T1/el unknown
- 2016-07-27 SM SM201600253T patent/SMT201600253B/it unknown
-
2017
- 2017-01-09 US US15/402,141 patent/US10507242B2/en active Active
-
2018
- 2018-10-24 HR HRP20181757TT patent/HRP20181757T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160932T1 (hr) | Kombinirana terapija za liječenje raka dojke | |
HRP20201656T1 (hr) | Neutralizacija inhibitornih putova u limfocitima | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
EA201691225A1 (ru) | Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение | |
HRP20180078T1 (hr) | VARIJANTE ANTI-TFPI PROTUTIJELA S DIFERENCIJALNIM VEZANJEM U ŠIROKOM RASPONU pH RADI POBOLJŠANE FARMAKOKINETIKE | |
EP4276114A3 (en) | Cd20 binding single domain antibodies | |
EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
MX2015016978A (es) | Proteinas de union a antigeno neutralizantes de citomegalovirus. | |
HRP20150279T1 (hr) | Fc inaäśice s promijenjenim vezanjem na fcrn | |
EA201590144A1 (ru) | Rspo3-связывающие агенты и их применение | |
EA201490622A1 (ru) | Агенты, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение | |
EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
ECSP21010450A (es) | Anticuerpos antisortilina y métodos para su uso | |
HRP20221088T1 (hr) | Protutijela i postupci uporabe | |
RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
EA202092460A1 (ru) | Антитела к ox40 и способы применения | |
WO2014205302A3 (en) | Lectin-like oxidized ldl receptor1 antibodies and methods of use | |
WO2014205300A3 (en) | Lectin-like oxidized ldl receptor1 antibodies and methods of use | |
EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
PH12020552235A1 (en) | Anti-cd40 antibodies for use in treating autoimmune disease | |
EA202092136A1 (ru) | Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства |